After NIH trial, EMA begins rolling review for remdesivir, setting up potential authorizations in US and Europe

A day after the NIH released positive results from their trial testing remdesivir in Covid-19, the EMA has announced the start of a rolling review process for the drug. With an FDA decision expected to arrive in the coming days, the news sets the stage for the Gilead antiviral to become the standard-of-care for the deadly virus in both the US and Europe.